Dyne Therapeutics Inc’s recent filing unveils that its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $1733.0 on Mar 13 ’25. In the deal valued at $12.12 per share,143 shares were sold. As a result of this transaction, Friedl-Naderer Johanna now holds 96,057 shares worth roughly $0.65 million.
Then, Scalzo Richard William sold 1,343 shares, generating $15,283 in total proceeds. Upon selling the shares at $11.38, the SVP, Head of Finance & Admin. now owns 122,330 shares.
Before that, Beskrovnaya Oxana sold 2,153 shares. Dyne Therapeutics Inc shares valued at $24,501 were divested by the Chief Scientific Officer at a price of $11.38 per share. As a result of the transaction, Beskrovnaya Oxana now holds 195,840 shares, worth roughly $1.33 million.
BMO Capital Markets initiated its Dyne Therapeutics Inc [DYN] rating to an Outperform in a research note published on March 12, 2025; the price target was $50. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early March with a ‘”a Sector outperform”‘ rating. Robert W. Baird began covering DYN with “an Outperform” recommendation on December 13, 2024. RBC Capital Mkts started covering the stock on November 26, 2024. It rated DYN as “an Outperform”.
Price Performance Review of DYN
On Tuesday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock fall -9.08% to $6.81. Over the last five days, the stock has lost -26.22%. Dyne Therapeutics Inc shares have fallen nearly -71.10% since the year began. Nevertheless, the stocks have fallen -74.24% over the past one year. While a 52-week high of $47.45 was reached on 01/02/25, a 52-week low of $7.26 was recorded on 04/08/25. SMA at 50 days reached $12.55, while 200 days put it at $27.79.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 6.24, which if violated will result in even more drops to 5.66. On the upside, there is a resistance level at 7.82. A further resistance level may holdings at 8.82. The Relative Strength Index (RSI) on the 14-day chart is 22.04, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.58%. Stochastics %K at 3.17% indicates the stock is a buying.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2025-03-14, growing by 1.49 million shares to a total of 12.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 10.9 million shares. There was a rise of 12.01%, which implies that there is a positive sentiment for the stock.
